FR3692M - Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire et hypnotique. - Google Patents

Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire et hypnotique.

Info

Publication number
FR3692M
FR3692M FR988116A FR988116A FR3692M FR 3692 M FR3692 M FR 3692M FR 988116 A FR988116 A FR 988116A FR 988116 A FR988116 A FR 988116A FR 3692 M FR3692 M FR 3692M
Authority
FR
France
Prior art keywords
hypnotic
therapy
amino acid
new amino
spasmolytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR988116A
Other languages
English (en)
Inventor
H Keberle
J Faigle
M Wilhelm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
BASF Schweiz AG
Original Assignee
Ciba Geigy AG
Ciba AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH853763A external-priority patent/CH446376A/de
Priority claimed from FR980779A external-priority patent/FR1431697A/fr
Application filed by Ciba Geigy AG, Ciba AG filed Critical Ciba Geigy AG
Priority to FR988116A priority Critical patent/FR3692M/fr
Application granted granted Critical
Publication of FR3692M publication Critical patent/FR3692M/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR988116A 1963-07-09 1964-09-15 Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire et hypnotique. Active FR3692M (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR988116A FR3692M (fr) 1963-07-09 1964-09-15 Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire et hypnotique.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH853763A CH446376A (de) 1963-07-09 1963-07-09 Verfahren zur Herstellung neuer Aminosäuren
CH672964 1964-05-22
FR980779A FR1431697A (fr) 1963-07-09 1964-07-06 Procédé de préparation de nouveaux acides aminés, entre autres l'acide gamma-amino-beta-(p-chlorophényl)butyrique
FR988116A FR3692M (fr) 1963-07-09 1964-09-15 Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire et hypnotique.

Publications (1)

Publication Number Publication Date
FR3692M true FR3692M (fr) 1965-11-15

Family

ID=25700075

Family Applications (2)

Application Number Title Priority Date Filing Date
FR988115A Active FR3677M (fr) 1963-07-09 1964-09-15 Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire, anticonvulsivant, hypnotique ou sédatif.
FR988116A Active FR3692M (fr) 1963-07-09 1964-09-15 Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire et hypnotique.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR988115A Active FR3677M (fr) 1963-07-09 1964-09-15 Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire, anticonvulsivant, hypnotique ou sédatif.

Country Status (9)

Country Link
US (1) US3471548A (fr)
BE (1) BE650258A (fr)
BR (1) BR6460727D0 (fr)
CH (1) CH449645A (fr)
DE (1) DE1493536B1 (fr)
ES (1) ES301814A1 (fr)
FR (2) FR3677M (fr)
GB (1) GB1017439A (fr)
SE (4) SE333151B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956314A (en) * 1970-07-24 1976-05-11 U.C.B., Societe Anonyme Derivatives of 2-pyrrolidinone
US3947579A (en) * 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3978216A (en) * 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4084000A (en) * 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
NL7706429A (nl) * 1977-06-10 1978-12-12 Univ Erasmus Werkwijze voor de bereiding van een geneesmid- del met angst en angstequivalenten opheffende werking en gevormd geneesmiddel met een derge- lijke werking.
NL8006135A (nl) * 1980-11-10 1982-06-01 Univ Erasmus Geneesmiddel met angst en angstequivalenten opheffende werking en werkwijze voor de bereiding van een dergelijk geneesmiddel.
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
WO1997022578A1 (fr) * 1995-12-20 1997-06-26 Farmarc Nederland B.V. Procede de resolution optique de 3-(p-chlorophenyl)-glutaramide
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
EA200300433A1 (ru) 2000-11-30 2003-10-30 Пфайзер Продактс Инк. Комбинация гамк-агонистов и ингибиторов альдегидредуктазы
KR20030059290A (ko) 2000-11-30 2003-07-07 화이자 프로덕츠 인코포레이티드 Ｇａｂａ 작용제 및 소르비톨 데하이드로게나제 억제제의혼합물
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
PT1660440E (pt) * 2003-08-20 2012-05-15 Xenoport Inc Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização
EP2354120A1 (fr) 2003-08-20 2011-08-10 XenoPort, Inc. Synthèse de promédicaments a base de carbamate d'acyloxyalkyle et leurs intermédiaires
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005082372A1 (fr) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINAISON DE MODULATEURS D'ACIDE γ-AMINOBUTYRIQUE ET D'ANTAGONISTES DU RECEPTEUR 5-HT1B
WO2007025177A2 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2377530A3 (fr) 2005-10-21 2012-06-20 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
US20100197789A1 (en) 2006-08-11 2010-08-05 National University Corporation Nagoya University Anti-obesity agent and use thereof
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
KR20090121388A (ko) * 2007-03-15 2009-11-25 썬 파마 어드밴스트 리서치 컴패니 리미티드 신규 전구약물
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2011113904A1 (fr) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Médicaments pour la prévention et le traitement d'une maladie associée à la dégénérescence des cellules ganglionnaires rétiniennes
EP3322691A4 (fr) 2015-07-13 2019-03-27 Piramal Enterprises Limited Procédé amélioré de préparation de baclofène et de son intermédiaire
CN106187794A (zh) * 2016-07-12 2016-12-07 安徽省逸欣铭医药科技有限公司 一种巴氯芬的绿色工业化生产方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125583A (en) * 1964-03-17 Hjnc oxchaxohxchc o oh

Also Published As

Publication number Publication date
SE348460B (fr) 1972-09-04
SE333151B (sv) 1971-03-08
BE650258A (fr) 1965-01-08
FR3677M (fr) 1965-11-08
ES301814A1 (es) 1965-01-01
DE1493536B1 (de) 1971-10-14
BR6460727D0 (pt) 1973-08-02
SE348462B (fr) 1972-09-04
SE348461B (fr) 1972-09-04
CH449645A (de) 1968-01-15
US3471548A (en) 1969-10-07
GB1017439A (en) 1966-01-19

Similar Documents

Publication Publication Date Title
FR3692M (fr) Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire et hypnotique.
FR3290M (fr) Nouvelles amines utilisables en thérapeutique, notamment comme inhibiteurs de la mono-aminoxydase.
FR308M (fr) Nouvelle pyridyl-éthyl-guanidine utilisable en thérapeutique.
FR302M (fr) Nouvelle m-butoxy-phénoxy-éthylamine utilisable en thérapeutique.
FR3439M (fr) Nouvelle quinazoline utilisable en thérapeutique, notamment comme analgésique.
FR3818M (fr) Nouvel imidazole utilisable en thérapeutique, notamment comme agent antischistosomien et antiamibien.
FR3416M (fr) Nouveau aminoacide utilisable en thérapeutique, notamment comme spasmolytique musculaire et hypnotique.
FR3734M (fr) Nouvelle pipérazine utilisable en thérapeutique, notamment comme agent hypotenseur.
FR3534M (fr) Nouvelle isoquinoléine utilisable en thérapeutique, notamment comme agent antitussif.
IL31021A0 (en) New n,n-dialkyl benzamides and their use as herbicides
FR2691M (fr) Nouveaux a-nor-b-homo-stéroides utilisables en thérapeutique, notamment comme gestagenes.
FR3006M (fr) Nouveau médicament utilisable notamment comme analgésique, antipyrétique et antirhumatismal.
FR1898M (fr) Nouvelle substance utilisable en thérapeutique.
FR1865M (fr) Nouvel éthyl-ammonium-hydroxyde, utilisable en thérapeutique, notamment comme médicament spasmolytique.
IL27811A (en) Thionosalicylic acid anilides,salts thereof and methods for their preparation
FR3170M (fr) Nouvelles composition thérapeutiques, notamment a effet analgésique et antipyrétique.
FR270M (fr) Nouvelles urées utilisables en thérapeutique.
OA00736A (fr) N-hydroxyméthyl-benzamides et thibenzamides chlorés utilisables notamment comme herbicides.
FR1733M (fr) Nouvelle urée utilisable en thérapeutique, notamment comme hypoglycémiant.
FR2998M (fr) Nouvelles guanidines utilisables en thérapeutique, notamment comme hypoglycémiants.
FR1013M (fr) Médicament analgésique, antithermique et antirhumatismal.
FR117M (fr) Nouveau biguanide utilisable en thérapeutique.
FR349M (fr) Nouvelle 1,3-dihydroxy-2-nitro-tricos-4-yne utilisable en thérapeutique.
FR353M (fr) Nouvelle quinoléine utilisable en thérapeutique.
FR3864M (fr) Nouvelles pipérazines utilisables en thérapeutique, notamment comme agents hypotenseurs.